Equities

Artrya Ltd

AYA:ASX

Artrya Ltd

Actions
Health CareHealth Care Providers
  • Price (AUD)0.255
  • Today's Change0.005 / 2.00%
  • Shares traded51.57k
  • 1 Year change+21.43%
  • Beta--
Data delayed at least 20 minutes, as of Jun 07 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Artrya Limited is a medical technology company focused on commercializing its artificial intelligence (AI) platform. The principal activities of the Company are the development of medical technology using AI to identify patients at risk of coronary artery disease. It is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop an overview of a patient at risk. The company has developed deep learning algorithms that allow for the prediction and prevention of acute coronary events. Its Artrya Salix is a computed tomography coronary angiography (CCTA) image analysis solution that enables physicians with AI to identify and analyze the extent and type of arterial plaque. This solution uses no external reading teams to validate cardiac scan data, allowing physicians direct control of their AI-supported patient scans. Artrya Salix provides solutions for physicians, administrators, payers and patients.

  • Revenue in AUD (TTM)0.00
  • Net income in AUD-11.56m
  • Incorporated2018
  • Employees--
  • Location
    Artrya Ltd1257 Hay Street, West PerthPERTH 6005AustraliaAUS
  • Phone+61 86478-7816
  • Websitehttps://www.artrya.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Freedom Care Group Holdings Ltd32.67m1.44m4.30m34.0013.564.092.220.13160.01330.01330.30160.0445.53--45.58--20.19-4.7730.12-5.5597.59--3.65-102.13----0.1012----111.86-----47.34--
Genetic Technologies Ltd8.49m-12.71m16.53m60.00--3.00--1.95-0.1126-0.11260.07520.04170.70289.844.20141,514.20-105.21-52.85-154.00-61.7053.5549.50-149.69-247.361.55--0.0736--27.83114.96-64.79--49.00--
Artrya Ltd0.00-11.56m19.28m----0.8111-----0.1472-0.14720.000.30210.00-------36.17---38.11--------------0.0435------35.09------
Emyria Ltd1.95m-11.95m23.72m----22.38--12.17-0.0363-0.03630.00620.00260.275--49.60---168.58-77.78-321.66-93.49-12.45-45.04-612.98-388.17---30.010.7573---12.62--29.98------
Cleo Diagnostics Ltd302.22k-3.92m24.08m----3.96--79.69-0.0305-0.03050.00240.0820.0502--3.76---65.13---76.78-------1,296.85-----28.110.00-------3,836.95------
Cryosite Ltd12.61m1.58m52.23m34.0033.1718.0322.534.140.03230.03230.25820.05930.591274.837.30--7.394.128.994.8860.8553.8812.508.562.29--0.4487--1.5115.043.30--10.72--
Microba Life Sciences Ltd6.54m-18.49m82.85m----1.68--12.67-0.0502-0.05020.01780.110.11192.679.26---31.64---37.61--46.55---282.64--3.11--0.0272--15.60---10.55------
Data as of Jun 07 2024. Currency figures normalised to Artrya Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.